Works Cited

1. Smith KM, Larive LL, Romanelli F. Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate. Am J Health-Syst Pharm. 2002;59(11):1067-1076.

2. Britt GC, McCance-Katz EF. A brief overview of the clinical pharmacology of "club drugs." Subst Use Misuse. 2005;40(9-10):1189-1201.

3. Rimsza ME, Moses KS. Substance abuse on the college campus. Pediatr Clin North Am. 2005;52(1):307-319.

4. Rome ES. It's a rave new world: rave culture and illicit drug use in the young. Cleve Clin J Med. 2001;68(6):541-550.

5. Jones CM, Clayton HB, Deputy NP, et al. Youth Risk Behavior Surveillance—United States, 2019. MMWR. 2020;69(Suppl-1):40-46.

6. American Addiction Centers. Ecstasy Statistics and History. Available at https://drugabuse.com/drugs/ecstasy/history-statistics. Last accessed December 13, 2021.

7. Monitoring the Future. Marijuana Use is Rising; Ecstasy Use is Beginning to Rise; and Alcohol Use is Declining Among U.S. Teens. Available at http://www.monitoringthefuture.org/pressreleases/10drugpr_complete.pdf. Last accessed December 12, 2021.

8. El-Mallakh RS, Abraham HD. MDMA (Ecstasy). Ann Clin Psychiatry. 2007;19(1):45-52.

9. Greene JP, Ahrendt D, Stafford EM. Adolescent abuse of other drugs. Adolesc Med Clin. 2006;17(2):283-318.

10. Substance Abuse and Mental Health Services Administration. The DAWN Report: Ecstasy-Related Emergency Department Visits by Young People Increased Between 2005 and 2011; Alcohol Involvement Remains a Concern. Available at https://www.samhsa.gov/data/sites/default/files/spot127-youth-ecstasy-2013/spot127-youth-ecstasy-2013.pdf. Last accessed December 15, 2021.

11. United Nations Office on Drugs and Crime. World Drug Report 2015. Available at https://www.unodc.org/documents/wdr2015/World_Drug_Report_2015.pdf. Last accessed December 15, 2021.

12. Morton J. Ecstasy: pharmacology and neurotoxicity. Curr Opin Pharmacol. 2005;5(1):79-86.

13. National Institute on Drug Abuse. MDMA (Ecstasy) Abuse. Available at https://www.drugabuse.gov/publications/research-reports/mdma-ecstasy-abuse/Introduction. Last accessed December 13, 2021.

14. National Drug Intelligence Center, Drug Enforcement Administration, United States Customs Service. Joint Assessment of MDMA Trafficking Trends. Johnstown, PA: National Drug Intelligence Center; 2000.

15. Sacco LN, Finklea K. Synthetic Drugs: Overview and Issues for Congress. Available at https://www.deadiversion.usdoj.gov/fed_regs/rules/2017/fr0301.htm. Last accessed December 14, 2021.

16. Baumeister D, Tojo LM, Tracy DK. Legal highs: staying on top of the flood of novel psychoactive substances. Ther Adv Psychopharmacol. 2015;5(2):97-132.

17. Klein M, Kramer F. Rave drugs: pharmacological considerations. AANA J. 2004;72(1):61-67.

18. Lexicomp Online. Available at https://online.lexi.com. Last accessed December 14, 2021.

19. Bang-Ping J. Sexual dysfunction in men who abuse illicit drugs: a preliminary report. J Sex Med. 2009;6(4):1072-1080.

20. Hahn I-H. MDMA Toxicity. Available at https://emedicine.medscape.com/article/821572-overview. Last accessed December 15, 2021.

21. Andresen H, Aydin BE, Mueller A, Iwersen-Bergmann S. An overview of gamma-hydroxybutyric acid: pharmacodynamics, pharmacokinetics, toxic effects, addiction, analytical methods, and interpretation of results. Drug Test Anal. 2011;3(9):560-568.

22. U.S. Drug Enforcement Administration. Drug Fact Sheet: GHB. Available at https://www.dea.gov/sites/default/files/2020-06/GHB-2020_0.pdf. Last accessed December 15, 2021.

23. Drasbek KR, Christensen J, Jensen K. Gamma-hydroxybutyrate-a drug of abuse. Acta Neurol Scand. 2006;114(3):145-156.

24. Pardi D, Black J. Gamma-hydroxybutyrate/sodium oxybate: neurobiology, and impact on sleep and wakefulness. CNS Drugs. 2006;20(12):993-1018.

25. Benzer TI. Gamma-Hydroxybutyrate Toxicity. Available at https://emedicine.medscape.com/article/820531-overview. Last accessed December 15, 2021.

26. van Noorden MS, Kamal R, de Jong CA, Vergouwen AC, Zitman FG. Gamma-hydroxybutyric acid (GHB) dependence and the GHB withdrawal syndrome: diagnosis and treatment. Ned Tijdschr Geneeskd. 2010;154:A1286.

27. Kamal RM, Schellekens A, De Jong Ca, Dijkstra BA. Baclofen as relapse prevention in the treatment of Gamma-Hydroxybutyrate (GHB) dependence: an open label study. BMC Psychiatry. 2015;15:91.

28. Li JH, Vicknasingam B, Cheung YW, et al. To use or not to use: an update on licit and illicit ketamine use. Subst Abuse Rehabil. 2011;2:11-20.

29. D'Orazio J. Hallucinogen Toxicity Treatment and Management. Treatment: Prehospital Care. Available at https://emedicine.medscape.com/article/814848-treatment. Last accessed December 15, 2021.

30. U.S. Drug Enforcement Administration. DEA Drug Fact Sheet: Rohypnol. Available at https://www.dea.gov/factsheets/rohypnol. Last accessed December 15, 2021.

31. U.S. Drug Enforcement Administration. Drugs of Abuse: A DEA Resource Guide, 2017 Edition. Available at https://www.dea.gov/sites/default/files/drug_of_abuse.pdf. Last accessed December 15, 2021.

32. Hall JA, Moore CBT. Drug-facilitated sexual assault: a review. J Forensic Leg Med. 2008;15(5):291-297.

33. Basheer C. Recent analytical strategies on "date-rape" drugs and its metabolites. J App Pharm Sci. 2011;1(6):21-28.

34. Brisset C, Leanza Y, Laforest K. Working with interpreters in health care: a systematic review and meta-ethnography of qualitative studies. Patient Educ Couns. 2013;91(2):131-140.

35. Hwa-Froelich DA, Westby CE. Considerations when working with interpreters. Commun Disord Q. 2003;24(2): 78-85.

36. Lynch EW. Developing cross-cultural competence. In: Lynch EW, Hanson MJ (eds). A Guide for Working with Children and Their Families: Developing Cross-Cultural Competence. 3rd ed. Baltimore, MD: Paul H. Brookes Publishing Co.; 2004.

37. Herndon E. Getting the most from language interpreters. Fam Pract Manag. 2004;11(6):37-40.

38. U.S. Drug Enforcement Administration. Gamma Hydroxybutyric Acid. Available at https://www.deadiversion.usdoj.gov/drug_chem_info/ghb.pdf. Last accessed December 15, 2021.

39. U.S. Drug Enforcement Administration. 2020 National Drug Threat Assessment (NDTA) Summary. Available at https://www.dea.gov/sites/default/files/2021-02/DIR-008-21%202020%20National%20Drug%20Threat%20Assessment_WEB.pdf. Last accessed December 14, 2021.

40. Monitoring the Future. National Survey Results on Drug Use: 2020 Overview, Key Findings on Adolescent Drug Use. Available at http://www.monitoringthefuture.org//pubs/monographs/mtf-overview2020.pdf. Last accessed December 11, 2021.

41. U.S. Department of Health and Human Services. Trends in the Prevalence of Marijuana, Cocaine, and Other Illegal Drug Use National YRBS: 1991–2019. Available at https://www.cdc.gov/healthyyouth/data/yrbs/factsheets/2019_us_drug_trend_yrbs.htm. Last accessed December 11, 2021.

42. UK Home Office. Letter from the Home Secretary to the Chair of the Advisory Council on the Misuse of Drugs. Available at https://www.gov.uk/government/publications/response-to-the-acmd-on-ghb-gbl-and-closely-related-compounds/letter-from-the-home-secretary-to-the-chair-of-the-advisory-council-on-the-misuse-of-drugs-accessible-version. Last accessed December 15, 2021.

Evidence-Based Practice Recommendations Citations

1. Clinical Effectiveness Group. UK National Guidelines on the Management of Adult and Adolescent Complainants of Sexual Assault 2011. London: British Association for Sexual Health and HIV; 2012. Available at https://www.bashhguidelines.org/media/1079/4450.pdf. Last accessed December 16, 2021.


Copyright © 2022 NetCE, P.O. Box 997571, Sacramento, CA 95899-7571
Mention of commercial products does not indicate endorsement.